Humana Inc.
$390.00+$10.00 (+2.6%)
Last close · Data as of Nov 20, 2026
- Market cap
- $42.0B
- P/E
- 35.4x
- Revenue
- $129.7B
- Net margin
- 0.9%
- ROCE
- 7.3%
Price chart
Technical chartScreen technicals →+74.7% over the last year
Daily closes.
Go deeper
Technical chart: candles, 28 indicators including moving averages, RSI and MACD, drawing tools and five colour themes
Performance
Price return, before dividends, to the 20 Nov 2026 close.
- 1M
- -8.7%
- 3M
- +2.4%
- 6M
- +28.2%
- 1Y
- +74.7%
- 5Y
- -10.3%
52-week range
Day change +$10.00 (+2.6%) from $380 to $390 · Last close Nov 20, 2026
Best weekday to invest, historically
The same weekly amount in HUM, bought on each weekday since 2021.
News & filings
What Humana filed, who traded, and what's next
How to read this
"News & filings" lists what the company itself has put on record with regulators, who inside it traded, the news that names it, and the next date we know of. Filings and releases are first-hand; news is third-party and may be thin for smaller companies. A day of insider filings is one row. Nothing here is a recommendation.
AI Summary
US StockConcernNet margin of 0.9% against a peer median of 18.2%.
Strengths (1)
- Cash on the balance sheet equals 47% of the company's market value.
Prices to the 20 Nov 2026 close · Financial year: fiscal 2025
Rule-based from financial data. Not advice.
About the company
Humana Inc. provides medical and specialty insurance products in the United States. It operates in two segments, Insurance and CenterWell.
Read moreShow less
Humana Inc. provides medical and specialty insurance products in the United States. It operates in two segments, Insurance and CenterWell. The Insurance segment offers individual Medicare Advantage products, including health insurance benefits, including wellness programs, chronic care management, and care coordination; individual Medicare stand-alone prescription drug products (PDP); group Medicare advantage and Medicare stand-alone PDP; Medicare supplements; specialty and ancillary insurance comprising dental, vision, life and disability; and administrative services to arrange health care services for active-duty and retired military personnel and dependents, as well as pharmacy benefit managers. Its CenterWell segment operates full-service, value-based senior focused primary care centers under the Conviva Senior Primary Care and CenterWell Senior Primary Care brands; a management services organization; CenterWell Home Health, a home health provider; and OneHome, which manages post-acute patient needs, as well as provides pharmacy and hospice solutions. The company was formerly known as Extendicare Inc. and changed its name to Humana Inc. in April 1974. Humana Inc. was founded in 1961 and is headquartered in Louisville, Kentucky.
- Sector
- Healthcare
- Shares outstanding
- 120.6M
Key statistics
Screen fundamentals →Valuation, profitability, growth and solvency at the latest close; hover a label for its meaning.
Valuation
- Market cap
- $42.0B
- P/E
- 35.4x
- P/B
- 2.4x
- EV / Sales
- 0.3x
- P/S
- 0.3x
- 52-week high
- $461.25
- 52-week low
- $163.67
Profitability
- Operating margin
- 1.7%
- Net margin
- 0.9%
- ROE
- 6.7%
- ROCE
- 7.3%
- ROA
- 2.4%
- Asset turnover
- 2.65
Growth
- RevenueFY2025, the latest fiscal year in the company's growth history.
- $129.7B
- Revenue growth, 1YFY2025, the latest fiscal year in the company's growth history.
- 10.1%
- Revenue CAGR, 3YFY2025, the latest fiscal year in the company's growth history.
- 11.8%
- Net profit growth, 1YFY2025, the latest fiscal year in the company's growth history.
- -1.6%
- Free cash flowFY2025, the latest fiscal year in the company's growth history.
- $375.0M
Solvency
- Debt / Equity
- 0.70
- Debt / Assets
- 0.25
- CFO / Net profit
- 0.78
- Cash / Market cap
- 47.4%
Where the revenue went
Some FY2025 lines are not reported, so the ones that are appear as a table.
| Line | FY2025 |
|---|---|
| Revenue | $129.7B |
| Gross profit | $129.7B |
| Pretax income | $1.6B |
| Tax and other | $367.0M |
| Net income | $1.2B |
Revenue and net profit
Revenue grew 10.1% in FY2025; net profit is the dashed line.
| Date | Revenue | Net profit |
|---|---|---|
| FY2022 | $92.9B | $2.8B |
| FY2023 | $106.4B | $2.5B |
| FY2024 | $117.8B | $1.2B |
| FY2025 | $129.7B | $1.2B |
Cash flows
FY2025: $921.0M from operations, $375.0M free after investment (dashed).
| Date | Operating cash flow | Free cash flow |
|---|---|---|
| FY2022 | $4.6B | $3.5B |
| FY2023 | $4.0B | $3.0B |
| FY2024 | $3.0B | $2.4B |
| FY2025 | $921.0M | $375.0M |
Growth
Latest fiscal year 2025: each figure with its change over the year before.
- Revenue
- $129.7B+10.1%1Y
- Net profit
- $1.2B-1.6%1Y
- Cash from operations
- $921.0M-68.9%1Y
- Free cash flow
- $375.0M-84.3%1Y
- Revenue CAGR, 3Y
- 11.8%
- Net profit CAGR, 3Y
- -24.9%
| Year | Revenue | EBITDA | Net profit | FCF | ROE | Revenue growth 1Y | Net profit growth 1Y |
|---|---|---|---|---|---|---|---|
| FY2025 | $129.7B | — | $1.2B | $375.0M | 6.7% | +10.1% | -1.6% |
Monthly returns
Month-by-month returns of HUM across the years, with the seasonal pattern.
Balance sheet
What the company owns and owes at the end of FY2025.
| Line | FY2025 |
|---|---|
| Assets | $48.9B |
| Current assets | — |
| Non-current assets | — |
| Liabilities | $31.2B |
| Current liabilities | — |
| Non-current liabilities | — |
| Equity | $17.7B |
| Paid-in capital | $3.6B |
| Retained earnings | $29.1B |
| Treasury stock | $14.4B |
| Minority interest | $80.0M |
Market cap against peers
8 peers: same sector, nearest by size.
Peers map
Healthcare companies placed by value, growth and quality; HUM highlighted.
P/E against peers
HUM trades at 35.4x earnings against a peer median of 36.2x.
Peer comparison
Same-sector peers by market cap, with the median.
| Company | Market cap | P/E | P/B | ROE | EV/EBITDA |
|---|---|---|---|---|---|
| Humana Inc.HUMthis company | $42.0B | 35.4x | 2.4x | 6.7% | — |
| Edwards Lifesciences CorporationEW | $50.4B | 46.9x | 4.9x | 10.4% | 33.2x |
| Cardinal Health, Inc.CAH | $47.2B | 30.3x | -17.0x | -56.1% | 16.7x |
| IDEXX Laboratories, Inc.IDXX | $44.5B | 42.0x | 27.7x | 66.0% | 30.1x |
| Becton, Dickinson and CompanyBDX | $41.2B | 24.6x | 1.6x | 6.6% | 12.1x |
| Alnylam Pharmaceuticals, Inc.ALNY | $40.5B | 129.2x | 51.4x | 39.8% | 61.6x |
| Agilent Technologies, Inc.A | $39.1B | 30.0x | 5.8x | 19.3% | 22.1x |
| Waters CorporationWAT | $37.0B | 57.5x | 14.4x | 25.1% | 36.7x |
| Zoetis Inc.ZTS | $33.3B | 12.5x | 10.0x | 80.2% | 9.9x |
| Peer median | — | 36.2x | 7.9x | 22.2% | 26.1x |
Year-to-date ROI
HUM since 1 January, against earlier years.
Historical volatility
HUM's day-to-day swings over 30, 60 and 180 days.
Financial statements
Income statement, balance sheet and cash flow as reported, grouped into plain-language lines.
Consolidated figures in USD, fiscal years, newest first.
| Line | FY2025 |
|---|---|
| RevenueTotal Revenue | $129.7B |
| Operating expenses | |
| Other operating expensesOther Operating Expenses | $15.9B |
| Depreciation and amortisationDepreciation And Amortization In Income Statement | $698.0M |
| Total expensesTotal Expenses | $128.1B |
| Interest and other | |
| Pretax incomePretax Income | $1.6B |
| TaxTax Provision | $250.0M |
| Net incomeNet Income | $1.2B |
| Per share | |
| Supplementary | |
| Other lines |
| Line | FY2025 |
|---|---|
| AssetsTotal Assets | $48.9B |
| Current assets | |
| Non-current assets | |
| LiabilitiesTotal Liabilities Net Minority Interest | $31.2B |
| Current liabilities | |
| Non-current liabilities | |
| EquityTotal Equity Gross Minority Interest | $17.7B |
| Supplementary |
| Line | FY2025 |
|---|---|
| Operating cash flowOperating Cash Flow | $921.0M |
| Cash from continuing operationsCash Flow From Continuing Operating Activities | $921.0M |
| Net income, continuing operationsNet Income From Continuing Operations | $1.2B |
| Depreciation and amortisationDepreciation And Amortization | $824.0M |
| Depreciation | $773.0M |
| Amortization cash flowAmortization Cash Flow | $51.0M |
| Amortization of intangiblesAmortization Of Intangibles | $51.0M |
| Stock-based compensationStock Based Compensation | $241.0M |
| Deferred taxDeferred Tax | $75.0M |
| Deferred income taxDeferred Income Tax | $75.0M |
| Operating gains and lossesOperating Gains Losses | $219.0M |
| Gain loss on investment securitiesGain Loss On Investment Securities | $50.0M |
| Gain loss on sale of businessGain Loss On Sale Of Business | $67.0M |
| Earnings losses from equity investmentsEarnings Losses From Equity Investments | $102.0M |
| Asset impairmentAsset Impairment Charge | $156.0M |
| Change in working capitalChange In Working Capital | -$1.8B |
| Other non-cash itemsOther Non Cash Items | — |
| Investing cash flowInvesting Cash Flow | $2.3B |
| Cash from continuing investingCash Flow From Continuing Investing Activities | $2.3B |
| Capital expenditureCapital Expenditure | -$546.0M |
| Purchase of PP&EPurchase Of PPE | -$546.0M |
| Sale of PP&ESale Of PPE | $23.0M |
| Net PP&E purchases and salesNet PPE Purchase And Sale | -$523.0M |
| AcquisitionsPurchase Of Business | -$81.0M |
| DisposalsSale Of Business | $115.0M |
| Net acquisitions and disposalsNet Business Purchase And Sale | $34.0M |
| Purchase of investmentsPurchase Of Investment | -$6.4B |
| Sale of investmentsSale Of Investment | $9.4B |
| Net investment purchases and salesNet Investment Purchase And Sale | $3.0B |
| Other investing changesNet Other Investing Changes | -$220.0M |
| Financing cash flowFinancing Cash Flow | -$1.2B |
| Cash from continuing financingCash Flow From Continuing Financing Activities | -$1.2B |
| Debt issuedIssuance Of Debt | $1.5B |
| Debt repaidRepayment Of Debt | -$1.1B |
| Net debt issuedNet Issuance Payments Of Debt | $431.0M |
| Short-term debt issuedShort Term Debt Issuance | $0.00 |
| Short-term debt repaidShort Term Debt Payments | -$102.0M |
| Net short-term debt issuedNet Short Term Debt Issuance | -$102.0M |
| Long-term debt issuedLong Term Debt Issuance | $1.5B |
| Long-term debt repaidLong Term Debt Payments | -$948.0M |
| Net long-term debt issuedNet Long Term Debt Issuance | $533.0M |
| Net common stock issuedNet Common Stock Issuance | -$151.0M |
| Common stock repurchasedCommon Stock Payments | -$151.0M |
| Share buybacksRepurchase Of Capital Stock | -$151.0M |
| Stock options exercisedProceeds From Stock Option Exercised | — |
| Dividends paidCash Dividends Paid | -$430.0M |
| Common dividends paidCommon Stock Dividend Paid | -$430.0M |
| Other financing chargesNet Other Financing Charges | -$1.3B |
| Change in cashChanges In Cash | $2.0B |
| Cash at the start of the yearBeginning Cash Position | $2.2B |
| Cash at the end of the yearEnd Cash Position | $4.2B |
| Free cash flowFree Cash Flow | $375.0M |
| Supplemental |
Learn while you research
Academy chapters picked for Humana Inc. and the metrics on this page.
- 01 Stock Valuation BasicsHow to think about what a fair price for a stock looks like.7 min read
- 02 Valuation Multiples ExplainedThis stock trades at a P/E of 35.4, learn when high multiples are justified.6 min read
- 03 Sector Analysis MattersHealthcare valuation is driven by pipelines and regulation, not just numbers.6 min read
- 04 Essential Stock RatiosP/E, P/B, EV/EBITDA, what they mean and when to use each.7 min read
- 05 How to Read a Cash-Flow StatementProfit can be manipulated; cash flow rarely lies.7 min read